Cargando…
Corrigendum to: Brigatinib dose rationale in anaplastic lymphoma kinase–positive non‐small cell lung cancer: Exposure–response analyses of pivotal ALTA study
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
John Wiley and Sons Inc.
2021
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8452300/ https://www.ncbi.nlm.nih.gov/pubmed/34414680 http://dx.doi.org/10.1002/psp4.12698 |